CUNY Advanced Science Research Center
85 St Nicholas Terrace,
New York, NY 10031
June 23rd and 24th 2016
Rui L. Reis
University of Minho
Professor Rui L. Reis, PhD, DSc, Hon. Causa MD, 49 years old, is the Vice-President for R&D of University of Minho (UMinho) in Portugal, Director of the 3B's Research Group on Biomaterials, Biodegradables and Biomimetics (www.3bs.uminho.pt) and of the ICVS/3B's Associate Laboratory (around 430 researchers), of UMinho. He is the CEO of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine. He is also the Global President of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) for 2016-2018, and the Editor-in-chief of the Journal of Tissue Engineering and Regenerative Medicine (IF= 5.2). He has funded and has been involved in several regenerative medicine, medical devices and consulting companies.
He is co-author of 958 ISI listed publications (743 full papers in scientific journals), around 225 book chapters, 30 patents and 8 books. He has around 1725 communications in international conferences. He is PI of projects totalizing around 35 MEuros, including the very prestigious ERC Advanced Grant, an ERA Chairs, 2 Twinning, 1 Teaming and 1 Marie Curie EC grants. He runs a research group of around 160 researchers with more than 60 PhD holders.
He was been awarded several major national and international scientific and innovation awards in Europe and the USA, including the Jean Leray and George Winter awards from the European Society for Biomaterials (ESB) and the Clemson Award for Contributions to the Literature from the Society for Biomaterials US (SFB). He is both a fellow of TERM (FTERM from TERMIS) and an International Fellow of Biomaterials Science and Engineering (FBSE from the International Union of Biomaterials Societies). He has been elected a foreigner member of the US National Academy of Engineering (NAE).
National Cancer Institute
Dr. Schneider received his B.Sc. in chemistry from the University of Akron in 1991, followed by a Ph.D. (1995) in chemistry from Texas A&M University. After which, he became a George W. Raiziss Postdoctoral Fellow at the University of Pennsylvania (1996-1999) studying protein design. He started his independent career at the University of Delaware (1999) in the Department of Chemistry and Biochemistry as a Francis Alison assistant professor. He remained at the University for ten years, with positions in Chemistry and Biochemistry, the Center for Translational Cancer Research, as well as Materials Science and Engineering, becoming full professor in 2010. After which, he moved to the National Cancer Institute, Center for Cancer Research where he serves as Chief of Chemical Biology, and recently appointed as Deputy Director of NCI. Dr. Schneider is also Editor in Chief of Biopolymers Peptide Science-Wiley, the Journal of the American Peptide Society.
The Schneider group designs and characterizes novel materials for use in tissue regenerative therapy, parenteral delivery of therapeutics, delivery of cells, and antibacterial therapy. The group is particularly interested in peptide and protein-based hydrogel materials formed by self-assembly mechanisms. Their work spans molecular conception, materials synthesis, nano- and bulk mechanical materials characterization, cell-material interactions, biocompatibility, and assessment of performance efficacy. Their basic research establishes how material composition and structure influences material function, and lays the foundation to ultimately translate materials to the clinic.
Joanna Aizenberg, PhD, pursues a broad range of research interests that include biomimetics, self-assembly, smart materials, bio-nano interfaces, crystal engineering, surface chemistry, nanofabrication, biomineralization, biomechanics and biooptics. She received the B.S. degree in Chemistry in 1981, the M.S. degree in Physical Chemistry in 1984 from Moscow State University, and the Ph.D. degree in Structural Biology from the Weizmann Institute of Science in 1996.
Joanna is the Director of the Kavli Institute for Bionano Science and Technology and Platform Leader in the Wyss Institute for Bioinspired Engineering at Harvard University. She has served at the Board of Directors of the Materials Research Society and at the Board on Physics and Astronomy of the National Academies. She served on the Advisory Board of Langmuir and Chemistry of Materials, on Board of Reviewing Editors of Science Magazine, and is an Editorial Board Member of Advanced Materials.
Aizenberg is elected to the American Academy of Arts and Sciences, American Association for the Advancement of Science; and she is a Fellow of American Physical Society and Materials Research Society. Dr. Aizenberg received numerous awards from the American Chemical Society and Materials Research Society, including Fred Kavli Distinguished Lectureship in Nanoscience, Ronald Breslow Award for the Achievement in Biomimetic Chemistry, Arthur K. Doolittle Award in Polymeric Materials, ACS Industrial Innovation Award, and was recognized with two R&D 100 Awards for best innovations in 2012 and 2013 for the invention of a novel class of omniphobic materials and watermark ink technologies.
University of Strathclyde
Duncan Graham is Research Professor of Chemistry and Deputy Head of Department for Pure and Applied Chemistry at the University of Strathclyde in Glasgow. He is currently Chair of the Editorial Board of Analyst and will serve in that role until 2018. He has been awarded numerous awards for his research including the RSCs SAC Silver medal (2004), Corday Morgan prize (2009), a Royal Society Wolfson Research Merit award (2010), the Craver Award from the Coblentz Society (2012), Fellows Award from the Society for Applied Spectroscopy (2012) and was elected to the fellowship of the Royal Society of Edinburgh (2008). He has published over 200 papers and graduated over 50 PhD students. He is a cofounder and director of Renishaw Diagnostics Ltd (2007) and has filed 16 patents with license deals on most of his portfolio. He completed at PhD in organic chemistry at the University of Edinburgh (1996) and his interests are in developing new diagnostic assays based on nanoparticles and spectroscopy with target molecules including DNA, RNA, proteins and small molecule biomarkers.
Memorial Sloan Kettering Cancer Center
Michelle S. Bradbury earned a BA in Chemistry from the University of Pennsylvania, an MS in Nuclear Engineering, and a PhD in the Radiological Sciences from the Massachusetts Institute of Technology. This was followed by her formal medical education, which led to board certification in Diagnostic Radiology, a Certificate of Added Qualification (CAQ) in Neuroradiology, and an additional fellowship in Molecular Imaging at MSKCC. She is an currently an Associate Attending Physician and an Associate Member of the Department of Radiology at MSKCC. She holds a Joint Appointment in the Molecular Pharmacology Program at Sloan Kettering Institute, and is an Associate Professor of Radiology at the Gerstner Sloan Kettering Graduate School and Weill Medical College of Cornell University. She is Co-Director of a U54 NCI-awarded MSK-Cornell Center for Translation of Cancer Nanomedicines, as well as the Director of Intraoperative Imaging and Co-Chair of the Innovations and Technology Team at MSK. She has more than 16 years of experience in translational molecular imaging/radiological sciences, coupled with 10 years of applied nanomaterials research. During this time, her work has focused on the co-development and translation of tumor-selective, ultrasmall particle-based imaging tools (C dots) to the clinic for surgical and other medical oncology applications. In the intraoperative setting, fluorescent imaging device co-development has been crucial. For therapeutically-driven studies, dual-modality C dots are being used as drug delivery vehicles to target genetic mutations in brain tumor models. Dr. Bradbury serves as a Principal Investigator of multiple clinical trials involving the C dot platform. A first-in-human clinical trial has already been completed in metastatic melanoma patients using FDA IND approved molecularly-targeted C dot tracer. Additional open clinical trials are intraoperative in nature, either utilizing fluorescent C dots and real-time optical imaging guidance to surgically treat cancer-bearing lymph nodes in melanoma and breast cancer patients or to assess targeted uptake and histologic distributions of the particle tracer in brain tumor patients for therapeutic management. At the other end of the spectrum, nanobiological evaluations, in particular, particle fate studies have addressed endocytotic pathway transport and lysosomal function in a concentration-dependent manner. Recent work has also addressed cell death programs activated in particle-exposed cancer cells. Dr. Bradbury has and continues to serve as a member of several national and international Scientific Advisory Boards in Nanomedicine and Drug Discovery and Development, and is a member of the Nanomedicine Drug Delivery Clinical Trial Working Group at the National Cancer Institute. She is the founding member of Elucida Oncology, Inc., a start-up focused on particle-based clinical trials.
University of Strathclyde
Gail McConnell is Chair of Biophotonics at the Strathclyde Institute of Pharmacy and Biomedical Sciences at the University of Strathclyde. Following a first degree in Laser Physics and Optoelectronics (1998) and PhD in Physics from the University of Strathclyde (2002), she obtained a Personal Research Fellowship from the Royal Society of Edinburgh (2003) and a Research Councils UK Academic Fellowship (2005), securing a readership in 2008. Since 2004, Gail has received over £9M of research funding from a range of sources including EPSRC, MRC, BBSRC, EU and industry. The work in Gail&s group involves the design, development and application of linear and nonlinear optical instrumentation for biomedical imaging, from the nanoscale to the whole organism. She is a Fellow of the Institute of Physics, and a Fellow of the Royal Microscopical Society.
Amedee des Georges
CUNY Advanced Science Research Center
Amedee des Georges is a structural biologist with particular expertise in single-particle cryo-electron microscopy. Des Georges received his B.S. and M.S. in Biochemistry from Université Pierre and Marie Curie in Paris before obtaining his Ph.D. degree from the University of Cambridge in 2008 for his work with Linda Amos at the MRC-Laboratory of Molecular Biology. He then joined the lab of Joachim Frank at Columbia University as a postdoctoral researcher. In addition of being a core faculty member of the ASRC Structural Biology Initiative, des Georges is a tenure-track assistant professor at the City College Department of Chemistry and Biochemistry.
Samuel K. Sia
Samuel Sia, an associate professor of Biomedical Engineering at Columbia University, has developed novel technologies for microfluidics-based methods for point-of-care diagnostics, both in an academic and industry setting (as a founder and chair of scientific advisory board of Claros Diagnostics, a startup company that has recently garnered European regulatory approval for a diagnostics product). Dr. Sia's work in global health diagnostics, specifically, has garnered coverage from Nature, Science, JAMA, Washington Post, BBC, NPR, Voice of America, Science News, Popular Science, Chemical and Engineering News, and MIT Technology Review. Sia is using the powerful techniques of microfluidics to build low-cost handheld devices for performing sophisticated medical tests on a small microchip. His lab-on-a-chip device has been tested in Rwanda to collect and analyze blood tests at a patient's bedside to diagnose infectious diseases. Dr. Sia has a B.Sc. in Biochemistry from the University of Alberta, and a Ph.D. in Biophysics from Harvard University. Dr. Sia completed a Postdoctoral program in Chemistry and Chemical Biology at Harvard University.